Advanced Heart Failure and Transplant Cardiology · New Orleans, LA
NPI
1477538726
Since 2005
Specialty
Advanced Heart Failure and Transplant Cardiology
Code 207RA0001X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1514 Jefferson Hwy
New Orleans, LA, 70121
Phone (504) 842-3925
Groups this clinician bills Medicare through
Medicare paid, 2024
$25K
681 services
Medicare patients, 2024
169
Average age 70
Drug cost, 2024
$11.0M
3,444 prescriptions
Company payments, 2025
$11K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Clement C Eiswirth Jr. was code 93793 (care management/coordination), 352 times for 12 patients. In total Clement C Eiswirth Jr. billed 681 services in 22 codes, and Medicare paid $25K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-05-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 93793 Care Management/Coordination | Facility | 352 | 12 | $7.60 | $2,676 |
| 99214 Office E&M - Established | Facility | 136 | 91 | $64.33 | $8,749 |
| 93750 External Electrocardiographic Monitoring | Facility | 46 | 19 | $28.63 | $1,317 |
| 99215 Office E&M - Established | Facility | 22 | 22 | $105.50 | $2,321 |
| 99214 Office E&M - Established | Office | 20 | 13 | $61.80 | $1,236 |
| 93451 Percutaneous Transcatheterization | Facility | 17 | 15 | $90.47 | $1,538 |
By year: 2022 $50K for 1,133 services; 2023 $27K for 732 services; 2024 $25K for 681 services.
Medicare prescription drug claims, 2024
In 2024, the drug Clement C Eiswirth Jr. prescribed most often to Medicare patients was Entresto (Sacubitril/Valsartan), with 359 prescriptions and refills. In total Clement C Eiswirth Jr. wrote 3,444 Medicare prescriptions that cost $11.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Entresto Sacubitril/Valsartan | 359 | 450 | 73 | $300K |
| Vyndamax Tafamidis | 315 | 315 | 41 | $6.9M |
| Metoprolol Succinate Generic | 244 | 597 | 74 | $4,105 |
| Spironolactone Generic | 190 | 384 | 64 | $1,274 |
| Potassium Chloride Generic | 174 | 311 | 64 | $3,188 |
| Furosemide Generic | 144 | 255 | 49 | $574 |
| Eliquis Apixaban | 143 | 195 | 25 | $113K |
| Jardiance Empagliflozin | 112 | 168 | 27 | $96K |
| Rosuvastatin Calcium Generic | 101 | 253 | 33 | $876 |
| Warfarin Sodium Generic | 100 | 184 | 30 | $786 |
| Atorvastatin Calcium Generic | 79 | 207 | 26 | $827 |
| Camzyos Mavacamten | 79 | 79 | 12 | $649K |
| Repatha Sureclick Evolocumab | 77 | 82 | Under 11 | $45K |
| Amlodipine Besylate Generic | 75 | 194 | 30 | $339 |
| Torsemide Generic | 74 | 130 | 21 | $1,910 |
Brand drugs: - claims; generic drugs: 2,140 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Clement C Eiswirth Jr. $11K ($11K in general payments such as food, travel and fees) from 8 companies. The largest payer was BridgeBio Pharma, Inc. with $11K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.